AstraZeneca PLC (AZN) Gross Margin: 81.68%
Is AstraZeneca PLC’s gross margin high or low?
AstraZeneca PLC's gross margin of 81.68% is in line with its 5-year average of 77.31%, near the high end of its 5-year range (66.76%–81.95%).
As of Friday, June 12, 2026. 0.21% above its 12-month average of 81.51%.
AZN Gross Margin Chart
AZN Average Gross Margin Chart
AZN Current vs Average Gross Margin Chart
AZN Gross Margin Metrics
GROSS MARGIN
81.68%
GROSS MARGIN AVG TTM
81.51%
GROSS MARGIN AVG 3Y
79.26%
GROSS MARGIN AVG 5Y
77.31%
GROSS MARGIN AVG 10Y
78.67%
GROSS MARGIN AVG 15Y
79.16%
GROSS MARGIN AVG 20Y
79.19%
CURRENT VS TTM AVG
+0.21%
CURRENT VS 3Y AVG
+3.06%
CURRENT VS 5Y AVG
+5.65%
CURRENT VS 10Y AVG
+3.82%
CURRENT VS 15Y AVG
+3.18%
CURRENT VS 20Y AVG
+3.14%
AZN Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 81.68% | 81.51% | 79.26% | 77.31% |
| Merck & Co., Inc. (MRK) | $298.29B | 75.91% | 74.15% | 73.03% | 71.89% |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 18.80% | 20.43% | 22.48% | 23.36% |
| Amgen Inc. (AMGN) | $191.09B | 71.46% | 66.16% | 69.53% | 71.51% |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 39.41% | 39.50% | 40.36% | 43.54% |
| AbbVie Inc. (ABBV) | $397.12B | 70.68% | 70.11% | 68.16% | 68.00% |
| Gilead Sciences, Inc. (GILD) | $156.28B | 79.35% | 78.55% | 78.10% | 78.28% |
| Abbott Laboratories (ABT) | $156.15B | 56.38% | 53.17% | 51.86% | 51.92% |
| Pfizer Inc. (PFE) | $149.18B | 69.35% | 68.05% | 62.23% | 63.06% |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 66.29% | 66.73% | 66.82% | 67.04% |
Gross Margin Analysis
Gross Margin
81.7%
(Revenue - COGS) / Revenue
AstraZeneca PLC Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Gross Margin FAQ
- What is the gross margin for AstraZeneca PLC (AZN)?
- The gross margin for AZN stock is 81.68%.
- Is AstraZeneca PLC's gross margin high or low?
- AstraZeneca PLC's gross margin of 81.68% is in line with its 5-year average of 77.31%, near the high end of its 5-year range (66.76%–81.95%).
- What is the TTM average gross margin for AstraZeneca PLC (AZN)?
- The TTM average gross margin for AZN stock is 81.51%.
- What is the 3Y average gross margin for AstraZeneca PLC (AZN)?
- The 3Y average gross margin for AZN stock is 79.26%.
- What is the 5Y average gross margin for AstraZeneca PLC (AZN)?
- The 5Y average gross margin for AZN stock is 77.31%.
- What is the 10Y average gross margin for AstraZeneca PLC (AZN)?
- The 10Y average gross margin for AZN stock is 78.67%.
- What is the 15Y average gross margin for AstraZeneca PLC (AZN)?
- The 15Y average gross margin for AZN stock is 79.16%.
- What is the 20Y average gross margin for AstraZeneca PLC (AZN)?
- The 20Y average gross margin for AZN stock is 79.19%.
AstraZeneca PLC Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 81.90% |
| 2024-12-31 | 81.12% |
| 2023-12-31 | 81.95% |
| 2022-12-31 | 72.06% |
| 2021-12-31 | 66.76% |
| 2020-12-31 | 80.09% |
| 2019-12-31 | 79.82% |
| 2018-12-31 | 77.66% |
| 2017-12-31 | 80.78% |
| 2016-12-31 | 82.06% |
| 2015-12-31 | 81.20% |
| 2014-12-31 | 77.99% |
| 2013-12-31 | 79.61% |
| 2012-12-31 | 80.72% |
| 2011-12-31 | 82.06% |
| 2010-12-31 | 80.80% |
| 2009-12-31 | 82.40% |
| 2008-12-31 | 79.12% |
| 2007-12-31 | 78.28% |
| 2006-12-31 | 79.00% |
| 2005-12-31 | 77.64% |
| 2004-12-31 | 75.76% |
| 2003-12-31 | 76.32% |
| 2002-12-31 | 74.67% |
| 2001-12-31 | 72.96% |
| 2000-12-31 | 100.00% |
| 1999-12-31 | 78.54% |
| 1998-12-31 | 82.06% |
| 1997-12-31 | 0.00% |
| 1996-12-31 | 0.00% |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot